Imunofan spray 45mkg / dose, 40 dose

Intranasally. When using, the bottle should be held vertically with the spray up. Remove the protective cap from the sprayer. Before the first use, fill the dosing pump by pressing the wide rim of the sprayer 3-4 times. Insert the nebulizer into the nasal passage with the head upright. Press the wide rim of the spray gun once until it stops. One dose of the drug contains 45 mcg of Imunofan. The daily dose should not exceed 180 mcg.

In the complex therapy of acute and chronic infectious and inflammatory diseases, accompanied by symptoms

intoxication and immunodeficiency state, Imunofan is prescribed 1 dose (45 mcg) in each nasal passage 2 times a day, every day for 10-15 days.

With opportunistic infections (cytomegalovirus and herpes infection, toxoplasmosis, chlamydia, pneumocystosis, cryptosporidiosis):

- 1 dose (45 mcg) in each nasal passage 2 times a day, daily, the course of treatment is 10-15 days. If necessary, it is possible to repeat the course in 2-4 weeks.

For chronic viral hepatitis and chronic brucellosis:

- 1 dose (45 mcg) in each nasal passage once a day, daily, the course of treatment is 10-15 days, to prevent relapse, repeated courses should be carried out in 4-6 months.

In the treatment regimen for patients with HIV infection:

- 1 dose (45 mcg) in each nasal passage once a day, every day, for 10-15 days. If necessary, it is possible to repeat the course in 2-4 weeks.

In the treatment of cancer patients in the scheme of radical combined treatment (chemo-radiation therapy and surgery):

- 1 dose (45 mcg) in each nasal passage once a day, daily, for 8-10 days before chemo-radiation therapy and surgery, followed by continuation of the course throughout the entire period of treatment.

In patients with a widespread tumor process (stage III - IV) of various localization in terms of complex or symptomatic therapy:

- 1 dose (45 mcg) in each nasal passage once a day, every day, for 8-10 days. If necessary and in the presence of pronounced symptoms of toxicosis, it is recommended to repeat the course.

Active ingredient: arginyl-alpha-aspartyl-lysyl-valyl-tyrosyl-arginine diacetate (in terms of anhydrous and acetic acid-free substance) 45 ?g / dose

Excipients: glycine (5 mg) sodium chloride (0.7 mg), benzalkonium chloride (0.014 mg), disodium edetate (0.007 mg), purified water (up to 0.14 ml)

• Hypersensitivity

• children's age up to 2 years.

• Application during pregnancy and during breastfeeding

Pharmacological properties
The drug has an immunoregulatory, detoxifying, hepatoprotective effect and causes inactivation of free radical and peroxide compounds. The pharmacological action is based on the achievement of three main effects: correction of the immune system, restoration of the balance of the oxidative-antioxidant reaction of the body and inhibition of multidrug resistance mediated by proteins of the transmembrane transport pump of the cell.

The effect of the drug begins to develop within 2 to 3 hours (fast phase) and lasts up to 4 months (medium and slow phases).

During the fast phase (duration - up to 2-3 days), the detoxification effect is manifested first of all - the antioxidant defense of the body is enhanced by stimulating the production of ceruloplasmin, lactoferrin, catalase activity; the drug normalizes lipid peroxidation, inhibits the breakdown of cell membrane phospholipids and the synthesis of arachidonic acid, followed by a decrease in blood cholesterol levels and the production of inflammatory mediators. In case of toxic and infectious liver damage, the drug prevents cytolysis, reduces the activity of transaminases and the level of bilirubin in the blood serum.

During the middle phase (starts after 2-3 days, duration - up to 7-10 days), there is an increase in the reactions of phagocytosis and death of intracellular bacteria and viruses. During the slow phase (it begins to develop on days 7-10, duration up to 4 months), the immunoregulatory effect of Imunofan is manifested - the restoration of disturbed parameters of cellular and humoral immunity. During this period, there is a normalization of the immuno-regulatory index, an increase in the production of specific antibodies is noted. The effect of Imunofan on the production of specific antiviral and antibacterial antibodies is equivalent to the effect of some therapeutic vaccines. Unlike the latter, the drug does not significantly affect the production of reaginic antibodies of the IgE class and does not enhance the immediate hypersensitivity reaction;Imunofan stimulates the formation of IgA in congenital insufficiency.

Imunofan effectively suppresses multidrug resistance of tumor cells and increases their sensitivity to the action of cytostatic drugs.

Side effects.
Individual intolerance is possible.

Interaction with other medicinal products.
In clinical practice, there have been no cases of interaction of Imunofan with other drugs.
The action of Imunofan does not depend on the production of PGE2 and the administration of the drug is possible in combination with anti-inflammatory (steroid and non-steroidal) drugs.